HIGH PERFORMANCE ANTIBODIES … AND MORE

Infectious Disease

Infectious Disease Research

Infectious diseases result from a host being exposed to a pathogen such as bacteria or viruses. Antibodies can be used to detect these pathogens or key targets that these pathogens use to infect a host. Antibodies can also be used to better treat and understand the diseases caused by these pathogens. ProSci offers various antibodies to aid researchers to have a better understanding of how to detect and treat infectious diseases.

View Infectious Disease Research Reagents

    Primary Antibodies

  • CD81 Antibody [1.3.3.22]

    Catalog Number: 33-829

    Clonality: Monoclonal

    Tested Applications: Flow, Func, IF, IHC-P, WB

    Species Reactivity: Human, Mouse, Rat

    Host Species: Mouse

    Conjugate: Unconjugated

    Size: 100 ug

    2 Image(s)

    • IHC testing of FFPE human lymph node with CD81 antibody (clone 1.3.3.22). Required HIER: boil tissue sections in 10mM citrate buffer, pH 6, for 10-20 min followed by cooling at RT for 20 min.
    • IHC testing of FFPE human tonsil with CD81 antibody (clone 1.3.3.22). Required HIER: boil tissue sections in 10mM citrate buffer, pH 6, for 10-20 min followed by cooling at RT for 20 min.

  • CXCR4 Antibody

    Catalog Number: 1012

    Clonality: Polyclonal

    Tested Applications: ELISA, IF, IHC, WB

    Species Reactivity: Human, Mouse, Rat

    Host Species: Rabbit

    Conjugate: Unconjugated

    Size: 0.02 mg, 0.1 mg

    9 Image(s)

    • <strong>Figure 1 Western Blot Validation of CXCR4 in HeLa Cells </strong><br> Loading: 15 μg of lysates per lane. Antibodies: 1012 (1 μg/mL), 1 h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
    • <strong>Figure 2 Independent Antibody Validation (IAV) via Protein Expression Profile</strong><br> Loading: 15 μg of lysates per lane. Antibodies: 1009 (1 μg/mL), 1012 (1 μg/mL), and beta-actin (1 μg/mL), 1 h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
    • <strong>Figure 3 Validation with CXCR4 siRNA Knockdown in HeLa Cells </strong><br> HeLa cells were transfected with control siRNAs (lane 1) or CXCR4 siRNAs (lane 2) Loading: 10 μg of HeLa whole cell lysates per lane. Antibodies: 1012 (2 μg/mL), 1 h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
    • <strong>Figure 4 Animal Species Reactivity </strong><br> Loading: Lysates/proteins at 20 μg per lane. Antibodies: 1009 (2 μg/mL) or 1012 (2 μg/mL). 1 h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
    • <strong>Figure 5 Immunofluorescence Validation of CXCR4 </strong><br>Immunofluorescent analysis of 4% paraformaldehyde-fixed HeLa cells labeling CXCR4 with 1012 at 4 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (red). Image showing both membrane and cytoplasmic staining on HeLa cell line.
    • <strong>Figure 6 Immunohistochemistry Validation of CXCR4 in Human Spleen</strong><br> Immunohistochemical analysis of paraffin-embedded human spleen tissue using anti-CXCR4 antibody (1012) at 5 μg/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚ C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.
    • <strong>Figure 7 KO Validation of CXCR4 by Flow Cytometry (Ödemis, et al., 2010) </strong><br> Astrocytes from wild-type or CXCR4 knockout mice were stained with primary antibodies against CXCR4 and FITC-labeled secondary antibodies, and subsequently subjected to flow cytometry. CXCR4−/− astrocytes (red) showed loss of CXCR4 cell-surface expression compared with wild-type cells (black).
    • <strong>Figure 8 Overexpression Validation of CXCR4 (Kozak et al., 2002) </strong><br> U87MG and U87MG-CXCR4 extracts were included as negative and positive controls, respectively, for CXCR4 detection with anti-CXCR4 antibodies.
    • <strong>Figure 9 WB Validation of CXCR4 in Human Metastatic Melanoma (Scala et al., 2006) </strong><br> CXCR4 protein was detected in the human metastatic melanoma cell lines and human melanoma cell line (colo38), but not in the human primary melanocytes (MPR1) with anti-CXCR4 antibodies.
2 Item(s)
per page
Shop By
Currently Shopping by:
  1. Remove This Item Conjugate: Unconjugated
  2. Remove This Item Tested Applications: Func
  3. Remove This Item Tested Applications: IHC
  4. Remove This Item Species Reactivity: Rat
  5. Remove This Item Species Reactivity: HIV-1
  6. Remove This Item Species Reactivity: MRSA
Clear All
Refine by
Product type
  1. Primary Antibodies (2)
Conjugate
  1. Unconjugated (2)
Host Species
  1. Mouse (1)
  2. Rabbit (1)
Modifications
  1. None (2)
Tested Applications
  1. ELISA (29)
  2. Flow (3)
  3. Func (1)
  4. ICC (4)
  5. IF (20)
  6. IHC (1)
  7. IHC-P (17)
  8. IP (1)
  9. WB (31)
Show Less Show More
Species Reactivity
  1. Bacteria (7)
  2. Fungus (1)
  3. HIV-1 (0)
  4. Human (15)
  5. Mouse (2)
  6. MRSA (0)
  7. Rat (2)
  8. Virus (48)
Show Less Show More
Clonality
  1. Monoclonal (1)
  2. Polyclonal (1)

Research Area

Custom Antibody Services

Product Type

Support

About ProSci

Resources

Contact ProSci

  • 12170 Flint Place
    Poway, CA 92064, USA
  •  
  • Toll-Free: +1 (888) 513 9525
  • Phone: +1 (858) 513 2638
  • Fax: +1 (858) 513 2692
  • Email: info@prosci-inc.com

Follow Us:

  • ProSci Facebook
  • ProSci Twitter
  • ProSci LinkedIn

  • ProSci Newsletter
  • ProSci Research Gate